Amyloid beta-peptide is produced by cultured cells during normal metabolism - PubMed (original) (raw)
. 1992 Sep 24;359(6393):322-5.
doi: 10.1038/359322a0.
Affiliations
- PMID: 1383826
- DOI: 10.1038/359322a0
Amyloid beta-peptide is produced by cultured cells during normal metabolism
C Haass et al. Nature. 1992.
Abstract
Alzheimer's disease is characterized by the extracellular deposition in the brain and its blood vessels of insoluble aggregates of the amyloid beta-peptide (A beta), a fragment, of about 40 amino acids in length, of the integral membrane protein beta-amyloid precursor protein (beta-APP). The mechanism of extracellular accumulation of A beta in brain is unknown and no simple in vitro or in vivo model systems that produce extracellular A beta have been described. We report here the unexpected identification of the 4K (M(r) 4,000) A beta and a truncated form of A beta (approximately 3K) in media from cultures of primary cells and untransfected and beta-APP-transfected cell lines grown under normal conditions. These peptides were immunoprecipitated readily from culture medium by A beta-specific antibodies and their identities confirmed by sequencing. The concept that pathological processes are responsible for the production of A beta must not be reassessed in light of the observation that A beta is produced in soluble form in vitro and in vivo during normal cellular metabolism. Further, these findings provide the basis for using simple cell culture systems to identify drugs that block the formation or release of A beta, the primary protein constituent of the senile plaques of Alzheimer's disease.
Comment in
- Alzheimer's disease. In search of the soluble.
Hardy J, Mullan M. Hardy J, et al. Nature. 1992 Sep 24;359(6393):268-9. doi: 10.1038/359268a0. Nature. 1992. PMID: 1406927 No abstract available.
Similar articles
- Secretion kinetics of Alzheimer's amyloid beta-protein differs from secreted beta-amyloid precursor protein.
Araki W, Kunishita T, Takahashi K, Ikeda S, Tabira T. Araki W, et al. Biochem Biophys Res Commun. 1995 Sep 14;214(2):490-5. doi: 10.1006/bbrc.1995.2313. Biochem Biophys Res Commun. 1995. PMID: 7677756 - beta-Amyloid, protein processing and Alzheimer's disease.
Haas C, Hung AY, Citron M, Teplow DB, Selkoe DJ. Haas C, et al. Arzneimittelforschung. 1995 Mar;45(3A):398-402. Arzneimittelforschung. 1995. PMID: 7763333 Review. - Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production.
Citron M, Oltersdorf T, Haass C, McConlogue L, Hung AY, Seubert P, Vigo-Pelfrey C, Lieberburg I, Selkoe DJ. Citron M, et al. Nature. 1992 Dec 17;360(6405):672-4. doi: 10.1038/360672a0. Nature. 1992. PMID: 1465129 - Secretion of beta-amyloid precursor protein cleaved at the amino terminus of the beta-amyloid peptide.
Seubert P, Oltersdorf T, Lee MG, Barbour R, Blomquist C, Davis DL, Bryant K, Fritz LC, Galasko D, Thal LJ, et al. Seubert P, et al. Nature. 1993 Jan 21;361(6409):260-3. doi: 10.1038/361260a0. Nature. 1993. PMID: 7678698 - The amyloid peptide precursor in Alzheimer's disease.
Octave JN. Octave JN. Acta Neurol Belg. 1995 Dec;95(4):197-209. Acta Neurol Belg. 1995. PMID: 8553793 Review.
Cited by
- Novel Monoclonal Antibody Specific toward Amyloid-β Binds to a Unique Epitope within the N-Terminal Region.
Paterno G, Moore BD, Bell BM, Gorion KM, Ran Y, Prokop S, Golde TE, Giasson BI. Paterno G, et al. Antibodies (Basel). 2024 Aug 9;13(3):68. doi: 10.3390/antib13030068. Antibodies (Basel). 2024. PMID: 39189239 Free PMC article. - Serum Beta-Secretase 1 Activity Is a Potential Marker for the Differential Diagnosis between Alzheimer's Disease and Frontotemporal Dementia: A Pilot Study.
Saraceno C, Cervellati C, Trentini A, Crescenti D, Longobardi A, Geviti A, Bonfiglio NS, Bellini S, Nicsanu R, Fostinelli S, Mola G, Riccetti R, Moretti DV, Zanetti O, Binetti G, Zuliani G, Ghidoni R. Saraceno C, et al. Int J Mol Sci. 2024 Jul 30;25(15):8354. doi: 10.3390/ijms25158354. Int J Mol Sci. 2024. PMID: 39125924 Free PMC article. - Comparison of the Amyloid Plaque Proteome in Down Syndrome, Early-Onset Alzheimer's Disease and Late-Onset Alzheimer's Disease.
Martá-Ariza M, Leitner DF, Kanshin E, Suazo J, Pedrosa AG, Thierry M, Lee EB, Devinsky O, Drummond E, Fortea J, Lleó A, Ueberheide B, Wisniewski T. Martá-Ariza M, et al. Res Sq [Preprint]. 2024 Jul 15:rs.3.rs-4469045. doi: 10.21203/rs.3.rs-4469045/v1. Res Sq. 2024. PMID: 39070643 Free PMC article. Preprint. - The duality of amyloid-β: its role in normal and Alzheimer's disease states.
Azargoonjahromi A. Azargoonjahromi A. Mol Brain. 2024 Jul 17;17(1):44. doi: 10.1186/s13041-024-01118-1. Mol Brain. 2024. PMID: 39020435 Free PMC article. Review. - The advent of Alzheimer treatments will change the trajectory of human aging.
Selkoe DJ. Selkoe DJ. Nat Aging. 2024 Apr;4(4):453-463. doi: 10.1038/s43587-024-00611-5. Epub 2024 Apr 19. Nat Aging. 2024. PMID: 38641654 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources